Table 1: The clinical and experimental characters of 8 patients enrolled from Feb 11, 2020 to Mar 23, 2020.
|
No. |
Age (Year) |
Sex |
Pathogen |
MIC mg/L |
Infection site |
ECMO |
Hemodyalysis on Baseline |
Baseline Creatinine |
Baseline eGFR |
Initial Dose |
Nasal feed vancomycin |
Therapy duration (Total/IV/Pre.)* |
Sub-optimal/ total troughs |
Overdose/ total peaks |
Ctrough/Cpeak |
Adjust dose |
Pathogen Clearance |
AKI |
AUC0-24 (h·mg/L) |
AUC0-24/MIC (h) |
|
1 |
64 |
M |
Staphylococcus haemolyticus |
2 |
Lung |
Yes |
No |
71.77 |
101.39 |
1000 mg Q12 h |
250 mg Q6 h |
28/28/5 |
4/16 |
2/14 |
4.63-23.6/17-47.7 |
Yes |
Yes |
1 |
676 |
338 |
|
2 |
81 |
M |
Enterococcus faecalis |
2 |
Blood-stream |
Yes |
Yes |
188.67 |
31.7 |
1000 mg Q12 h |
250 mg Q6 h |
39/5/3 |
5/13 |
3/9 |
5.9-34.2/21.8-49.9 |
Yes |
Yes |
NA |
488 |
244 |
|
3 |
62 |
M |
Enterococcus faecium |
≤ 0.5 |
Lung |
Yes |
No |
77.4 |
92 |
1000 mg Q12 h |
No |
25/25/4 |
0/1 |
0/0 |
11.8/NA |
No |
Yes |
NA |
456 |
912 |
|
4 |
75 |
M |
Enterococcus faecium |
≤ 0.5 |
Lung |
Yes |
Yes |
85.62 |
80.13 |
500 mg Q8 h |
250 mg Q6 h |
17/13/4 |
0/3 |
1/1 |
19.5-26.6/41.7 |
Yes |
Yes |
3 |
869 |
1738 |
|
5 |
57 |
F |
Staphylococcus haemolyticus |
1 |
Blood-stream |
No |
No |
46.88 |
107.93 |
1000 mg Q12 h |
250 mg Q6 h |
13/12/2 |
0/1 |
1/1 |
12.1/41.43 |
No |
Yes |
NA |
370 |
370 |
|
6 |
70 |
M |
Staphylococcus haemolyticus |
1 |
Lung |
No |
Yes |
79.82 |
88.09 |
1000 mg Q12 h |
No |
11/11/3 |
0/1 |
0/0 |
15.1/NA |
No |
Yes |
NA |
984 |
984 |
|
7 |
63 |
F |
Emperical (NA) |
NA |
Lung |
Yes |
No |
31.67 |
193.99 |
1000 mg Q12 h |
125 mg Q6 h |
11/10/6 |
0/1 |
0/1 |
14.3/34.8 |
No |
NA |
2 |
457 |
NA |
|
8 |
65 |
M |
Enterococcus faecium |
≤ 0.5 |
Lung |
No |
Yes |
146.48 |
43.37 |
1000 mg Q12 h |
No |
5/5/5 |
0/0 |
0/1 |
NA/24.6 |
No |
Yes |
NA |
674 |
1349 |
|
Mean |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
622 |
848 |
|
SD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
218 |
566 |